<SEC-DOCUMENT>0001104659-22-092556.txt : 20220818
<SEC-HEADER>0001104659-22-092556.hdr.sgml : 20220818
<ACCEPTANCE-DATETIME>20220818161521
ACCESSION NUMBER:		0001104659-22-092556
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220818
FILED AS OF DATE:		20220818
DATE AS OF CHANGE:		20220818

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		221177662

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2224098d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN PRIVATE
ISSUER</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>PURSUANT TO RULE 13a-16
OR 15d-16 OF THE </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>SECURITIES EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of August 2022</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39446</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Exact Name of Registrant as Specified in Its
Charter</I>)</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive office)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation&nbsp;S&#45;T&nbsp;Rule&nbsp;101(b)(1):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation&nbsp;S&#45;T&nbsp;Rule&nbsp;101(b)(7):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2022, CureVac N.V. (the &#8220;Company&#8221;)
issued a press release announcing the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, developed in collaboration
with GlaxoSmithKline (&#8220;GSK&#8221;). The vaccine candidate is based on the Company&#8217;s second-generation mRNA backbone and is
designed to specifically protect against the Omicron variant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information included in this Form 6-K (including
Exhibit 99.1, but excluding the statements of the Company&#8217;s Chief Development Officer contained in Exhibit&nbsp;99.1 hereto) is
hereby incorporated by reference into the Company&#8217;s Registration Statement on Form F-3 (File No. 333-259613).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 50%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 3%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;Franz-Werner&nbsp;Haas,&nbsp;LLD,&nbsp;LLM</FONT></TD>
    <TD STYLE="vertical-align: top; width: 23%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 18, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 86px; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="width: 10px; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-top: 5pt; text-align: center"><A HREF="tm2224098d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 5pt"><A HREF="tm2224098d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">CureVac N.V. Press Release dated August 18, 2022.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2224098d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><IMG SRC="tm2224098d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CureVac Starts Phase
1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Phase 1 dose-escalation study to be conducted at clinical sites in the
U.S., the UK, Australia, and the Philippines</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Milestone demonstrates CureVac&rsquo;s continued execution on comprehensive
clinical program of second-generation vaccine candidates for infectious diseases</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>T&Uuml;BINGEN, Germany/ BOSTON, USA &ndash;
August 18, 2022</B> &ndash; CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines
based on messenger ribonucleic acid (&ldquo;mRNA&rdquo;), today announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine
candidate CV0501, administered as a booster dose to previous COVID-19 vaccination. Developed in collaboration with GSK, CV0501 is based
on CureVac&rsquo;s second-generation mRNA backbone and is designed to specifically protect against the Omicron variant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Licensed COVID-19 vaccines that encode
for the original virus variant, continue to protect against severe disease and hospitalization, but they are increasingly challenged by
immune evasion of new variants such as Omicron,&rdquo; said CureVac interim Chief Development Officer Dr. Ulrike Gnad-Vogt. &ldquo;As
we extend the clinical studies of our second-generation backbone into modified mRNA, targeting the Omicron variant will further explore
the full potential of our improved second-generation design as a booster vaccination for a relevant variant.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CV0501 study follows the start of a Phase
1 study in March 2022 that evaluates an unmodified second-generation COVID-19 vaccine candidate CV2CoV, encoding for the original virus
variant. The comprehensive approach to evaluate both an unmodified and a modified, second-generation vaccine candidate against COVID-19
is expected to identify the best-performing candidate for later-stage clinical development. In line with this approach, data from both
studies are expected to be reported as a combined data set.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Phase 1 dose-escalation study will be conducted
at clinical sites in the U.S., the UK, Australia, and the Philippines and is expected to enroll up to 180 healthy, COVID-19-vaccinated
adults to evaluate the safety, reactogenicity and immunogenicity of a single booster dose of CV0501 in the dose range of 12&micro;g to
50&micro;g. Additional dose levels below 12&micro;g and above 50&micro;g may be evaluated if supported by safety and immunogenicity data
at these dose levels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">COVID-19 studies are being conducted alongside
CureVac and GSK&rsquo;s jointly developed influenza vaccine program, in which clinical evaluation of the unmodified seasonal influenza
candidate CVSQIV and the modified candidate FLU SV mRNA have similarly been initiated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CureVac-GSK infectious disease collaboration
was first announced in July 2020. It focuses on the development of new products based on CureVac&rsquo;s mRNA technology for different
targets in the field of infectious diseases. The collaboration was extended in February 2021 to also include jointly developed vaccine
candidates for COVID-19. In 2022, the companies broadened their development strategy to test modified mRNA technologies in addition to
unmodified mRNA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font-size: 10pt; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2224098d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About CV0501</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CV0501 is CureVac&rsquo;s first COVID-19 vaccine
candidate applying chemically modified mRNA from the COVID-19 vaccine program developed in collaboration with GSK. It is based on CureVac&rsquo;s
advanced second-generation mRNA backbone. CV0501 encodes for the prefusion stabilized full-length spike protein of the SARS-CoV-2 Omicron
variant and is formulated within lipid nanoparticles (LNPs). As for all vaccines candidates applying the second-generation mRNA backbone,
CV0501 was designed with specifically optimized non-coding regions to exhibit improved mRNA translation for increased and extended protein
expression compared to the first-generation mRNA backbone. A clinical study testing the use of an unmodified mRNA candidate, CV2CoV, in
SARS-CoV-2 is currently being conducted in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac (Nasdaq: CVAC) is a global biopharmaceutical
company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing
this versatile biological molecule for medical purposes. The principle of CureVac&rsquo;s proprietary technology is the use of optimized
mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July
2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based
on CureVac&rsquo;s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19
vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline
across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has
its headquarters in T&uuml;bingen, Germany, and has more than 1,000 employees across its sites in Germany, the Netherlands, Belgium,
Switzerland and the U.S. Further information can be found at <U>www.curevac.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white"><B>CureVac
Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">Dr. Sarah Fakih,
Vice President Corporate Communications and Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">CureVac, T&uuml;bingen,
Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">T: +49 7071
9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">M: +49 160
90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>sarah.fakih@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white"><B>CureVac
Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bettina J&ouml;dicke-Braas, Manager Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">T: +49 7071 9883-1087</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>bettina.joedicke-braas@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font-size: 10pt; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><IMG SRC="tm2224098d1_ex99-1img01.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains statements that constitute
 &ldquo;forward looking statements&rdquo; as that term is defined in the United States Private Securities Litigation Reform Act of 1995,
including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or
its wholly owned subsidiaries CureVac AG, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH,
CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the &ldquo;company&rdquo;) regarding future events or future
results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company&rsquo;s
vaccine and treatment candidates and the company&rsquo;s strategies, financing plans, growth opportunities and market growth. In some
cases, you can identify such forward-looking statements by terminology such as &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project,&rdquo; or &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
 &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo; &ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative of these
terms or similar expressions. Forward-looking statements are based on management&rsquo;s current beliefs and assumptions and on information
currently available to the company. However, these forward-looking statements are not a guarantee of the company&rsquo;s performance,
and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other
variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial
markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense
and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability
to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from
increasing competition and consolidation in the company&rsquo;s industry, the effects of the COVID-19 pandemic on the company&rsquo;s
business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection,
ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such
risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements.
Many of these risks are outside of the company&rsquo;s control and could cause its actual results to differ materially from those it thought
would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake,
and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such
statements to reflect future events or developments, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For further information, please reference the
company&rsquo;s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting
EDGAR on the SEC website at <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font-size: 10pt; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2224098d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2224098d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! *D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBLS5=?
MT[1E'VN;]X1D1(,L?P[?C4RG&"O)V1<(2G+E@KLTZ*XW_A)]:U@,-$THB/.W
MSY3G'\AG\Z6U\/>(;B[AGU+5\(CJYB1B0<'.,# KG^L\S_=Q;\]E^)U?4N1?
MO9J/EN_N1V-%%%=1Q!1110 4444 %%%(S*BEF("@9)/84 4]2U:QT>!9[^X$
M,;-M4D$Y/T )JG%XKT&8@+JEN,_WVV?SQ7)Q'_A._%HF*'^R+ ?=;H_/I_M8
M_(5Z"T$+H$>)&0# 4J",5M*$864MSDI5:E9N4+<O3?7N_0C@O[.Z_P"/>[@F
M_P"N<@;^56*S)_#NC7/^MTNT)]1$%/YCFJ,OA2.-MVFZGJ%ACHD<Q>/_ +Y;
M/\ZBT'U-7*JOLI^C_P SH:*P%_X2;3TPPM-60=P?(E/\U_E3[3Q58378LKL2
MV%[D#R+E=I)/3!Z&CD?34%7C>TM'Y_Y[?B;E%%%0;!1110!B^*=6DT?17G@P
M)I'$49(SM)R<_D#6!X4\-Q7\']KZH/M+S,3&LAW \XRWJ<YKI]<TF/6M+>T=
MMC9#1O\ W6'3_/O7'Z1K=[X5D_LW5[:3[*&.QP/N\\E?[PKSJ]HXA2J_!;3L
MGYGK86\L+*%#X[Z]VO(] 1$C0)&JHBC 51@"L;4KJ>+Q1HUNDK+#*)O,0'AL
M+D9K1LM1L]1B\RTN8YE[[3R/J.HK,UVTOO[0T[4[&W6Y>T+AH"X4L&&,@FNJ
MJ[PO#NMNUSBH1M5<9Z.SW[V=M_,W:Y:POKJ3PIJUP]Q(TT33A')Y7 XQ]*L?
MVUKW;PT__@6O^%,L])O+?PE?6LJ W=RLK^6ISAF'"YK.<W.7N7T3Z-=-#6G3
M5./OVU<>J?778I:4L-WI=O<77B:[BG=<NGVI!@_0C-6="NY_^$EO+%-1DOK&
M.$.LCL'PV1QN'U-2:1X7T]=)MA?:=%]JV?O-W)S^!IVDZ7/IGB6]$$+1:6\0
M,:ALKO\ ES@9^M90A47(VNW5WVZW_$WJ5:4O:).^]KJ-M^EM?0RDU6&ZOK_^
MTM>NK)HKEXXHH6"C8#@'[IK3TF2PGOT%KXAOKJ106\IY 58=\_**KPPZKHMY
M?)%HRW\-Q<-.DHF5<;NV"#5VUU+5FNHD?PV8$9@K2BX4[ 3R<8YI4[IKGWOV
MEW[WL.K9Q?L]K=X=ETM?OUN85QJ=_P"$_%:)?W=Q<Z1=#Y'E.[R__K@]?8U9
M\;:W(4BT+33YEY>X#%#T0]OQ_E]:WO$&A0>(-,:TF.QP=T4@ZHW^'K7-^#/#
M4]H\FKZHDK7L>8H4;JJJ-N>?88'M]:]J,H-<[W7X]CY:I3K1DZ,?AEU[+JO\
MBQ<6Y\+Z';Z+H_SZK>MA6[YQ\SGT '2K7AV\GTZ\D\.ZG,7N(AOM96_Y;1]>
MOJ.?\BH++0+_ %>]EU?5Y[NPNR3'!%;2!3'$.Q.#G-+JGA*4(NH66HW\^I6O
MSV_VB4."1SMZ#KTZT-Q?NR>OZ^O8<8U(VJ0CHME?[/IW>_W%GQ%/=R:WHVEV
M]Y+:Q79E,KPX#_*H( )'%3?\(U)_T,&L_P#?]?\ XFJFK0:K<S:+K5MIV^YM
M/,\VS>0*WSK@X;IQC^5._M_Q%_T*;_\ @8O^%39\JY;?@:-PYY.HGY:2VLNW
MF=#:P&UM8X3-+,4&/,E.6;ZFJVJ:-8:Q;F&]MUDXPKXPR>X/:I[&:>XLHI;F
MV-M,PR\)?=L/ID=:HZUXAT_0X"UQ*&G(_=P*<NY[<=OK624N;3<Z9NFJ=Y_#
MY_\ !.<\-:K?:?XGN/#6H3M<(F?L\C\M@#<!GT*\^V*[FN*\+Z)?76N3^)=6
MC,,TN?)A(P5!&,GTP. .M=K5UK<VGS]3'!<_L_>VN[7WMT"BBBLCK"HKBV@N
MHC%<0I+&>JNH(J6BAJ^C&FT[HY._\"6<TWGV%Q)9OU"J-R@^W.1^=16FF^+-
M-NX<7Z7=MO <,^X[<\_>&>GH:[&BN9X2G?FC=/R=CK6.K./+.TEYJ_X[A111
M72<8445'/%Y\#Q>9)'N&-\9PP^AH!DE%8<^GPVLMM%+K>I1O<R>5"IF!WOM9
M\#*G^%6/X5,=$D_Z#.J?]_$_^(JK1[F?-/\ E_%&M161_83'KK&J'_MLH_DM
M)_PCT1/SZEJK>WVQQ_+%%H]Q<T_Y?Q1L5%+<P6XS-/'&/]MP/YUE_P#"+:4W
M^MCN)O\ KK=2M_-JDA\-:'#@II=H3ZM&&_GFG:/<+U>R^_\ X!#=^+M#LV"&
M_2:0]$MP9"?^^<BH(_$MW?$C3=!O91VDN,0)^9SFMV&V@MQB"&.(>B*%_E4M
M%X+9$\E5O65O1?J_\CFI]-\2:J0+K4X=.@[QV()<_5SC'X5>TOPWINDX>*'S
M;GJUS-\\C'UR>GX5KT4.I)JVR'&A!2YGJ_/7^ON"BJTM]'%J%M9%7:6X5W7:
M.%5,9)/U91^-1:EJUII4:-<NP+_=51DGD#Z 9(&20,D#N*@V+U%4[#5++4T9
MK2=)&3&],_,F>FX=1G!QZ]1D5<H **** "BBB@ HHHH *Q/$\MS'IR"VL;NZ
M99HKAOLQ4;5BD1R#E@3N"D8 )-;=% '(G6AJ%_IUS+:QSI!,[PC3Y6NF5S&R
MCS $ C)#..3CU(J:;Q3<V=K>PW]FEMJ<"K*L2EI8S"S*HDWX4$+N^89&-IY
M(-=.  20.O6EH QO#4NI7?AV"76+BTGNY0Q=K(_NP"3A003D@8!(/7I7&3>'
M=-T](/)\+0Q-)=W,<^JQ6QFGM$5V$3#&9"S+M^<<+U/I7IE% '._\)'!%J%O
M DJG3XK?==7,^4,9)Q&Q+8&"4D!/KMKG[/5[_3]'&G:;!=W8GOK@V]U#$91%
M:>83N!Z$_-M0'KP3\H->A8'IUHZ4 <QH$FIVVK2VDVG:E%I<L?F027UPL\D<
M@/S(6#N=I!!&3P0PZ8 N:WJ]S:7,-A8J@NI87G\R6%Y41%95^ZGS,2SJ..@R
M3TP=NLV[TR2?7M-U..55^RQS0R*1RZ2!3@'_ 'HT/YT <Y_PE&NW&JVMK%ID
M<+PPI-?V\@!D;,6]A%EANPQ" @$%@V2NWYI],\0ZQ-I0OKZS,,DQB00F"11"
M[N1CYU5FPI7/ !;@'GCKJSM=@N[C1+I+ *UZJB2W5S@&1"&4$_4"@##;6KZ,
M)>W5DRR1PW 1Q;NNZ/S(1YGE'YU !)*GGY#4=EI]YXGT1;B^OH79I9!'M"NI
M@+JP5O+8#=F-3E6XZ<]:[&B@#%T3PW:Z+=WM^K&6_OUB%U-C:'\M2J87HH"G
M%;5%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
